Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin liposomal
- Development stage
- Unknown
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Daunorubicin liposomal (DaunoXome) is an anthracycline antineoplastic agent encapsulated in a liposomal preparation to protect the drug from chemical and enzymatic degradation, reduce protein binding, and decrease uptake by non-target tissues[1]. The liposomal formulation may increase accumulation in tumors. Daunorubicin exerts its cytotoxic effects primarily by intercalating between DNA base pairs, inhibiting topoisomerase II activity, and stabilizing the DNA-topoisomerase II complex, leading to single- and double-strand DNA breaks. It may also inhibit polymerase activity and trigger free-radical DNA damage[1].
- Brand names
- DaunoXome
- Other names
- daunorubicin citrate liposomedaunorubicin citrate liposome injection
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin liposomal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin liposomal.